Nebula Research & Development LLC Biocryst Pharmaceuticals Inc Transaction History
Nebula Research & Development LLC
- $1.17 Trillion
- Q2 2025
A detailed history of Nebula Research & Development LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Nebula Research & Development LLC holds 286,509 shares of BCRX stock, worth $2.05 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
286,509Holding current value
$2.05 Million% of portfolio
0.22%Shares
1 transactions
Others Institutions Holding BCRX
# of Institutions
316Shares Held
202MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$147 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$143 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$60.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$60.5 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$40.9 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.33B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...